Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder
Zimmerman AW, Singh K, Connors SL, Liu H, Panjwani AA
Published in Molecular Autism
Methodology
15-week randomized parallel double-blind placebo-controlled trial with open-label and no-treatment extensions over 36 weeks in children aged 3-12 with ASD.
Key Findings
Treatment effects on the primary outcome (Ohio Autism Clinical Impressions Scale) were not statistically significant between sulforaphane and placebo at 7 and 15 weeks; effect sizes were positive but non-significant.
Conclusions
Sulforaphane did not significantly improve the general level of autism versus placebo in this trial, though it was safe and well tolerated.
Limitations
Small sample with attrition, single-site, possible underpowering for modest effects.
Supplements Studied
Treatment effects on the primary outcome measure, the Ohio Autism Clinical Impressions Scale (OACIS), in the general level of autism were not significant between SF and PL groups at 7 and 15 weeks.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Not specified
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.